Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has provided an announcement.
IRLAB Therapeutics reported full-year 2025 results showing net sales of SEK 57.5 million, a widened operating loss of SEK 93.4 million and year-end cash of SEK 81.9 million, while maintaining an average of 31 employees and seeing its share price decline to SEK 1.97. The company advanced its pipeline with a Phase Ib study of IRL757 in Parkinson’s disease and apathy now underway in Europe funded by MSRD, received strong backing from international experts for its drug pirepemat, confirmed attractive market potential for mesdopetam in levodopa-induced dyskinesia, and initiated a collaboration with Biomia to apply its ISP platform to new CNS compounds, developments that strengthen its clinical strategy despite ongoing losses.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish biopharmaceutical company focused on discovering and developing treatments for central nervous system (CNS) disorders, with a particular emphasis on Parkinson’s disease and related symptoms. The company uses its proprietary ISP platform to design and evaluate new drug candidates targeting unmet medical needs in neurological indications.
Average Trading Volume: 201,816
Technical Sentiment Signal: Sell
Current Market Cap: SEK134.5M
For a thorough assessment of IRLAB.A stock, go to TipRanks’ Stock Analysis page.